Drug intelligence / Profile preview

GS-4321

Development stage: Phase 2
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

GS-4321 is an investigational antiviral drug being developed for the treatment of **chronic hepatitis delta** (CHD), a severe form of viral hepatitis caused by hepatitis delta virus (HDV) infection. It is currently being studied in a Phase 1/2 clinical trial to evaluate its safety, tolerability, pharmacokinetics, and antiviral activity in both healthy subjects and participants with CHD. Detailed information regarding GS-4321’s exact mechanism of action, molecular target, or pharmacological class has not been publicly disclosed in available sources. The drug is considered for both safety (Phase 1) and efficacy (Phase 2) in escalating dose regimens for HDV infection[2][5][6][8].

Targets

preS1 (HBV presurface protein 1)

Beyond the preview

Go deeper on GS-4321.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-4321.

Explore the full profile